Percheron Therapeutics (ASX:PER) submitted a non-binding proposal to a pharmaceutical company to in-license a new drug development program focusing on a rare neurological disease, according to a Monday Australian bourse filing.
The proposal remains subject to further negotiations, as well as the execution of a definitive agreement, the filing said.
The firm estimated that at this stage it would take eight to 12 weeks to negotiate and sign a definitive agreement.
It plans to continue to evaluate alternative opportunities in parallel to the proposal.
The firm's shares jumped 8% in recent Monday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。